Enfortumab vedotin - Astellas Pharma/Seagen
Alternative Names: AGS-22C3; AGS-22CE; AGS-22M6E; AGS-22ME; AGS-M6; ASG-22CE; ASG-22M6E; ASG-22ME; Enfortumab; Enfortumab vedotin; Enfortumab vedotin-ejfv; PADCEVLatest Information Update: 23 Jul 2024
At a glance
- Originator Agensys; Seattle Genetics
- Developer Astellas Pharma; Astellas Pharma Global Development; Merck & Co; Seagen; Utah State University
- Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Urogenital cancer
- Phase III Bladder cancer
- Phase II Prostate cancer; Solid tumours
Most Recent Events
- 16 Jul 2024 Merck Sharp & Dohme plans phase I/II KEYMAKER-U04 trial in Urogenital-cancer (Late-stage disease, Metastatic disease, Combination therapy) in South Korea and Taiwan in August 2024 (IV) (NCT06483334)
- 10 Jul 2024 Merck Sharp & Dohme initiates a phase I/II KEYMAKER-U04 trial for Urogenital cancer (Second-line therapy or greater, Metastatic disease, Late-stage disease, Combination trial) in South Korea and Taiwan (IV) (NCT06483334)
- 31 May 2024 Efficacy and adverse events data from a phase II trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)